For the quarter ending 2025-12-31, VTGN made $303K in revenue. -$18,900K in net income. Net profit margin of -6237.62%.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total revenues | 303 | 258 | 244 | -15 |
| Research and development | 14,223 | 15,915 | 11,678 | 10,207 |
| General and administrative | 5,626 | 4,396 | 4,370 | 4,273 |
| Total operating expenses | 19,849 | 20,311 | 16,048 | 14,480 |
| Loss from operations | -19,546 | -20,053 | -15,804 | -14,495 |
| Other income, net | - | - | - | 1 |
| Interest income, net | 647 | 630 | 711 | 855 |
| Other income | 0 | 6 | -2 | - |
| Loss before income taxes | -18,899 | -19,417 | -15,095 | -13,635 |
| Income taxes | 0 | 0 | 0 | 0 |
| Net loss | -18,899 | -19,417 | -15,095 | -13,635 |
| Unrealized gain (loss) on marketable securities | -1 | 13 | -4 | -6 |
| Comprehensive loss | -18,900 | -19,404 | -15,099 | -13,641 |
| Basic, net loss per common share (in dollars per share) | -0.45 | -0.54 | -0.47 | -0.44 |
| Diluted, net loss per common share (in dollars per share) | -0.45 | -0.54 | -0.47 | -0.44 |
| Weighted average common shares outstanding, basic (in shares) | 42,234,405 | 35,749,160 | 31,930,665 | -61,070,625 |
| Weighted average common shares outstanding, diluted (in shares) | 42,234,405 | 35,749,160 | 31,930,665 | -61,070,625 |
Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. (VTGN)